Premium
Discordant human epidermal growth factor receptor 2 overexpression in primary and metastatic upper gastrointestinal adenocarcinoma signifies poor prognosis
Author(s) -
Hedner Charlotta,
Tran Lena,
Borg David,
Nodin Björn,
Jirström Karin,
Eberhard Jakob
Publication year - 2016
Publication title -
histopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.626
H-Index - 124
eISSN - 1365-2559
pISSN - 0309-0167
DOI - 10.1111/his.12744
Subject(s) - metastatic adenocarcinoma , adenocarcinoma , human epidermal growth factor receptor 2 , epidermal growth factor receptor , medicine , epidermal growth factor , oncology , primary (astronomy) , pathology , receptor , cancer research , cancer , breast cancer , physics , astronomy
Aims Targeted therapy with trastuzumab has proved to be effective for patients with gastric cancer overexpressing the human epidermal growth factor receptor 2 ( HER 2). Further studies are needed to determine the best method for assessment of HER 2 overexpression. Moreover, the prognostic value of HER 2 overexpression, including the significance of tumour heterogeneity, remains unclear. Methods and results HER 2 overexpression and gene copy alterations were assessed by immunohistochemistry and silver in‐situ hybridization, respectively, on tissue microarrays with primary tumours and a subset of paired lymph node metastases from 174 patients with oesophageal or gastric adenocarcinoma. Cox proportional hazards modelling was applied to assess the prognostic impact of HER 2 overexpression, intratumoural heterogeneity and conversion from primary tumour to metastasis. The correlation between protein expression and gene amplification was in line with previous studies. Primary–metastatic conversion was observed in 12.9% of the cases. HER 2 overexpression or intratumoural heterogeneity was not prognostic, but primary–metastatic conversion was an independent predictor of a shorter overall survival (hazard ratio = 4.93). Conclusions As trastuzumab is emerging as an important targeted therapy for patients with upper gastointestinal cancer, these results underline the importance of further studies addressing the occurrence and clinical significance of discrepant HER 2 expression in primary tumours and metastases.